Annual report [Section 13 and 15(d), not S-K Item 405]

Business combinations - Proforma Information (Details)

v3.25.1
Business combinations - Proforma Information (Details) - USD ($)
$ in Thousands
5 Months Ended 12 Months Ended
Jun. 01, 2023
May 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]          
Acquisition-related costs incurred by TCR2       $ 7,300  
Gain on bargain purchase       22,049  
Share-based compensation expense     $ 12,051 11,773 $ 18,240
TCR2 Therapeutics          
Business Acquisition [Line Items]          
Share-based compensation expense   $ 1,000     11,400
TCR2 Therapeutics          
Business Acquisition [Line Items]          
Revenue       60,281 27,148
Net loss       (177,312) $ (301,879)
Acquisition-related costs incurred by TCR2       9,000  
Gain on bargain purchase $ 22,049     22,000  
Acquisition-related costs       $ 7,346